1.
|
9 p, 525.7 KB |
Phase IIa Proof-of-Concept Evaluation of the Antiviral Efficacy, Safety, Tolerability, and Pharmacokinetics of the Next-Generation Maturation Inhibitor GSK3640254
/
Spinner, Christoph D. (Technical University of Munich) ;
Felizarta, Franco (Office of Franco Felizarta) ;
Rizzardini, Giuliano (University of the Witwatersrand) ;
Philibert, Patrick (Hôpital Europen de Marseille) ;
Mitha, Essack (Newtown Clinical Research) ;
Domingo, Pere (Institut d'Investigació Biomèdica Sant Pau) ;
Stephan, Christoph J. (Universitätsklinikum Frankfurt) ;
Degrosky, Michelle (ViiV Healthcare) ;
Bainbridge, Veronica (GlaxoSmithKline) ;
Zhan, Joyce (GlaxoSmithKline) ;
Dumitrescu, Teodora Pene (GlaxoSmithKline) ;
Jeffrey, Jerry L. (ViiV Healthcare. Research Triangle Park) ;
Xu, Jianfeng (GlaxoSmithKline) ;
Halliday, Fiona (GlaxoSmithKline) ;
Gan, Jianjun (GlaxoSmithKline) ;
Johnson, Mark (ViiV Healthcare. Research Triangle Park) ;
Gartland, Martin (ViiV Healthcare. Research Triangle Park) ;
Joshi, Samit R. (ViiV Healthcare) ;
Lataillade, Max (ViiV Healthcare) ;
Universitat Autònoma de Barcelona
GSK3640254 (GSK'254) is a next-generation human immunodeficiency virus type 1 (HIV-1) maturation inhibitor with pharmacokinetics (PK) supporting once-daily therapy. This phase IIa double-blind (sponsor-unblinded), randomized, placebo-controlled, adaptive study evaluated antiviral effect, safety, tolerability, and PK of once-daily GSK'254 monotherapy administered with food (moderate-fat meal) in HIV-1-positive, treatment-naive adults. [...]
2022 - 10.1093/cid/ciab1065
Clinical Infectious Diseases, Vol. 75 Núm. 5 (january 2022) , p. 786-794
|
|
2.
|
10 p, 656.0 KB |
Lack of Clinical Relevance of Bilastine-Food Interaction in Healthy Volunteers : A Wheal and Flare Study
/
Coimbra, Jimena (Institut d'Investigació Biomèdica Sant Pau) ;
Puntes, Montserrat (Institut d'Investigació Biomèdica Sant Pau) ;
Gich, Ignasi (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia) ;
Martínez, Joan (Institut d'Investigació Biomèdica Sant Pau) ;
Molina, Pol (Institut d'Investigació Biomèdica Sant Pau) ;
Antonijoan Arbós, Rosa Ma (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia) ;
Campo, Cristina (FAES FARMA S.A.) ;
Labeaga, Luis (FAES FARMA S.A.)
The aim of this study was to compare the pharmacodynamic activity of bilastine administered under fasting and fed conditions in healthy volunteers. In this randomized, open-label, two-period, crossover study involving 24 healthy subjects, once-daily oral bilastine 20 mg was administered for 4 days under fasting and fed conditions, with a 7-day washout period. [...]
2022 - 10.1159/000524856
International Archives of Allergy and Immunology, Vol. 183 (june 2022) , p. 1241-1250
|
|
3.
|
12 p, 2.3 MB |
Monitoring of gene expression in tacrolimus-treated de novo renal allograft recipients facilitates individualized immunosuppression : results of the IMAGEN study
/
Sommerer, Claudia (Heidelberg University Hospital (Alemanya)) ;
Brunet, M. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Budde, K. (Charité University Hospital Berlin) ;
Millán, O. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Guirado, Luis (Institut d'Investigació Biomèdica Sant Pau) ;
Glander, P. (Charité University Hospital Berlin) ;
Meuer, S. (Institute of Immunology. University Hospital Heidelberg) ;
Zeier, M. (Heidelberg University Hospital (Alemanya)) ;
Giese, Thomas (Heidelberg University Hospital (Alemanya))
Aims: Calcineurin inhibitors (CNI) have a small therapeutic window, and drug monitoring is required. Pharmacokinetic monitoring does not correlate sufficiently with clinical outcome. Therefore, the expression of nuclear factor of activated T cells (NFAT)-regulated genes in the peripheral blood has been suggested as a potentially useful immune monitoring tool to optimize CNI therapy. [...]
2021 - 10.1111/bcp.14794
British Journal of Clinical Pharmacology, Vol. 87 Núm. 10 (october 2021) , p. 3851-3862
|
|
4.
|
10 p, 696.8 KB |
Pharmacokinetics and Pharmacodynamics of Meropenem by Extended or Continuous Infusion in Low Body Weight Critically Ill Patients
/
Luque, Sonia (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Benítez-Cano, Adela (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Larrañaga, Leire (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Sorlí, Luisa (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Navarrete-Rouco, Maria Eugenia (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Campillo, Núria (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Carazo, Jesús (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Ramos, Isabel (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Adalia, Ramón (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Grau, Santiago (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Universitat Autònoma de Barcelona
Background : Pathophysiological changes such as extreme body weights in critically ill patients with severe infections may alter the pharmacokinetics (PK) of antimicrobials, leading to treatment failure or toxicity. [...]
2021 - 10.3390/antibiotics10060666
Antibiotics, Vol. 10 (june 2021)
|
|
5.
|
12 p, 646.0 KB |
Randomized, open-label, blinded-endpoint, crossover, single-dose study to compare the pharmacodynamics of torasemide-PR 10 mg, torasemide-IR 10 mg, and furosemide-IR 40 mg, in patients with chronic heart failure
/
Ballester, Maria Rosa (Institut d'Investigació Biomèdica Sant Pau) ;
Roig, Eulàlia (Institut d'Investigació Biomèdica Sant Pau) ;
Gich, Ignasi (Institut d'Investigació Biomèdica Sant Pau) ;
Puntes, Montserrat (Institut d'Investigació Biomèdica Sant Pau) ;
Delgadillo Duarte, Joaquin (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia) ;
Santos, Benjamín (Ferrer Internacional, S.A.) ;
Antonijoan Arbós, Rosa Ma. (Rosa María) (Institut d'Investigació Biomèdica Sant Pau) ;
Universitat Autònoma de Barcelona
Diuretics are the primary treatment for the management of chronic heart failure (HF) symptoms and for the improvement of acute HF symptoms. The rate of delivery to the site of action has been suggested to affect diuretic pharmacodynamics. [...]
2015 - 10.2147/DDDT.S86300
Drug Design, Development and Therapy, Vol. 9 (august 2015) , p. 4291-4302
|
|
6.
|
14 p, 1.9 MB |
Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer
/
Rodón, Jordi (Hospital Universitari Vall d'Hebron) ;
Carducci, Michael (Johns Hopkins Kimmel Cancer Center) ;
Sepulveda-Sánchez, Juan M. (Hospital Universitario 12 de Octubre (Madrid)) ;
Azaro, Analía (Hospital Universitari Vall d'Hebron) ;
Calvo, Emiliano (Centro Integral Oncológico Clara Campal-HM CIOCC (Madrid, Espanya)) ;
Seoane Suárez, Joan (Hospital Universitari Vall d'Hebron) ;
Braña, Irene (Hospital Universitari Vall d'Hebron) ;
Sicart, Elisabet (Hospital Universitari Vall d'Hebron) ;
Gueorguieva, Ivelina (Eli Lilly and Company) ;
Cleverly, Ann (Eli Lilly and Company) ;
Pillay, N. Sokalingum (Eli Lilly and Company) ;
Desaiah, Durisala (Eli Lilly and Company) ;
Estrem, Shawn T. (Eli Lilly and Company) ;
Paz-Ares, Luis (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Holdhoff, Matthias (Johns Hopkins Kimmel Cancer Center) ;
Blakeley, Jaishri (Johns Hopkins University) ;
Lahn, Michael M.. (Eli Lilly and Company) ;
Baselga Torres, Josep, 1959-2021, (Hospital Universitari Vall d'Hebron) ;
Universitat Autònoma de Barcelona
Purpose Transforming growth factor-beta (TGF-β) signaling plays a key role in epithelial-mesenchymal transition (EMT) of tumors, including malignant glioma. Small molecule inhibitors (SMI) blocking TGF-β signaling reverse EMT and arrest tumor progression. [...]
2014 - 10.1007/s10637-014-0192-4
Investigational New Drugs, Vol. 33 (december 2014) , p. 357-370
|
|